Analysts Set Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Price Target at $34.33

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have been given a consensus rating of “Hold” by the nine brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $34.3333.

Several equities research analysts recently weighed in on LKFT shares. Weiss Ratings restated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, May 26th. Wall Street Zen cut Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Zacks Research raised Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Finally, Morgan Stanley began coverage on Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, July 10th. They issued an “equal weight” rating and a $30.00 price target for the company.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

Large investors have recently bought and sold shares of the business. Madison Avenue Partners LP grew its stake in Lakefront Biotherapeutics American Depositary Shares by 0.8% in the 4th quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock worth $72,371,000 after buying an additional 17,394 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 2,490.1% during the third quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company’s stock valued at $49,083,000 after purchasing an additional 1,362,229 shares during the period. UBS Group AG grew its holdings in Lakefront Biotherapeutics American Depositary Shares by 128.4% in the 4th quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock worth $11,427,000 after acquiring an additional 196,445 shares during the last quarter. Millennium Management LLC raised its position in Lakefront Biotherapeutics American Depositary Shares by 121.9% during the 4th quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock valued at $11,097,000 after purchasing an additional 186,452 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in Lakefront Biotherapeutics American Depositary Shares by 2,245.7% in the first quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock worth $2,783,000 after acquiring an additional 115,946 shares during the period. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Price Performance

LKFT stock opened at $28.12 on Friday. Lakefront Biotherapeutics American Depositary Shares has a 1-year low of $26.42 and a 1-year high of $37.78. The business has a fifty day moving average price of $28.74 and a 200-day moving average price of $30.63. The stock has a market capitalization of $1.85 billion, a P/E ratio of -19.94 and a beta of 0.25.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $1.52. The business had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $11.26 million. As a group, analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -10.83 earnings per share for the current year.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.